Browse > Article
http://dx.doi.org/10.22246/jikm.2021.42.3.375

Effects of Korean Medicine in Idiopathic Pulmonary Fibrosis Patients - A Retrospective Chart Review  

Hong, Sung-eun (Division of Allergy, Immune & Respiratory System, Dept. of Internal Medicine, Graduate School, Kyung Hee University)
Kang, Sung-woo (Division of Allergy, Immune & Respiratory System, Dept. of Internal Medicine, Graduate School, Kyung Hee University)
Park, Ji-won (Division of Allergy, Immune & Respiratory System, Dept. of Internal Medicine, Graduate School, Kyung Hee University)
Jang, Kwon-jun (Division of Allergy, Immune & Respiratory System, Dept. of Internal Medicine, Graduate School, Kyung Hee University)
Park, Su-hyeon (Division of Allergy, Immune & Respiratory System, Dept. of Internal Medicine, Graduate School, Kyung Hee University)
Kim, Kwan-il (Division of Allergy, Immune & Respiratory System, Dept. of Internal Medicine, Graduate School, Kyung Hee University)
Bu, Yung-min (Dept. of Herbal Pharmacology, College of Korean Medicine, Kyung Hee University)
Jung, Hee-jae (Division of Allergy, Immune & Respiratory System, Dept. of Internal Medicine, Graduate School, Kyung Hee University)
Lee, Beom-joon (Division of Allergy, Immune & Respiratory System, Dept. of Internal Medicine, Graduate School, Kyung Hee University)
Publication Information
The Journal of Internal Korean Medicine / v.42, no.3, 2021 , pp. 375-384 More about this Journal
Abstract
Objective: This study was designed to analyze the clinical features of idiopathic pulmonary fibrosis patients who attended a Korean medicine hospital and the treatment effects through retrospective chart reviews. Methods: The medical records of 82 outpatients who had been diagnosed with idiopathic pulmonary fibrosis and visited the Allergy, Immune, and Respiratory System Department of Kyung Hee Korean Medicine Hospital from 8 January 2015 to 8 January 2021 were retrospectively reviewed. To assess the treatment outcomes, we used the FVC (Forced Vital Capacity), DLCO (Diffusing capacity of the Lung for CO), 6-minute walk test, and HRCT (High Resolution Computed Tomography). Results: The study group consisted of 28 females and 54 males. The median age of the patients was 67.98±11.44 years. The chief complaints were cough (n=51) and dyspnea (n=49). Other frequent symptoms were general weakness (n=8), weight loss (n=4), and a fever (n=2). A total of 77 (93.90%) patients were prescribed Korean herbal medicine, and 52 (63.41%) patients were treated with acupuncture, moxibustion, cupping therapy, ICT, or pharmacopuncture. After treatments, FVC, DLCO, the 6-minute walk test, and HRCT were maintained or worsened slightly. Conclusions: This study presented the characteristics of idiopathic pulmonary fibrosis patients treated by Korean medical therapies, and further studies of Korean medical treatments for idiopathic pulmonary fibrosis patients would be valuable.
Keywords
idiopathic pulmonary fibrosis; traditional Korean medicine; interstitial pulmonary disease;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M, et al. Presentation, diagnosis and clinical course of the spectrum of progressive- fibrosing interstitial lung diseases. European Respiratory Review 2018;27(150):180076.   DOI
2 Saito S, Alkhatib A, Kolls JK, Kondoh Y, Lasky JA. Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF). Journal of thoracic disease 2019;11(Suppl 14):S1740.   DOI
3 Son JY, Choi KH, Yoo HJ, Kwon OG, Park K, Kim HJ, et al. A Clinical Case Report of Diffuse Interstitial Lung Disease. The Journal of Internal Korean Medicine 2008;fal:111-6.
4 전국한의과대학 폐계내과학교실. 폐계내과학. 서울: 도서출판 나도; 2019, p. 464.
5 Richeldi L, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012;67(5):407-11.   DOI
6 du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, et al. 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. European Respiratory Journal 2014;43(5):1421-9.   DOI
7 Kwon BS, Song JW. New Diagnostic Guidelines for Idiopathic Pulmonary Fibrosis. Korean Journal of Medicine 2019;94(2):173-81.   DOI
8 Uh ST. Idiopathic Pulmonary Fibrosis: New Concept of Pathogenesis and Treatment. J Korean Med Assoc 2009;52(1):22-9.   DOI
9 Scott J, Johnston I, Britton J. What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. British Medical Journal 1990;301(6759):1015-7.   DOI
10 Ichikado K, Suga M, Mul er NL, Taniguchi H, Kondoh Y, Akira M, et al. Acute interstitial pneumonia: comparison of high-resolution computed tomography findings between survivors and nonsurvivors. American journal of respiratory and critical care medicine 2002;165(11):1551-6.   DOI
11 Jung HJ, Jung GJ, Jung SK, Rhee HK. Liripois Tuber contributes to the chemotaxis of eosinophils and secretion of cytokines in A549 human epithelial cells. The Journal of Korean Oriental Chronic Disease 2005;10(1):1-20.
12 Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS /JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. American journal of respiratory and critical care medicine 2011;183(6):788-824.   DOI
13 Ahn JM, Joo HJ, Park JH, Park JW, Kim KI, Jung HJ, et al. The Effects of Lung-Moistening Herbal Medicines on Bleomycin-Induced Pulmonary Fibrosis Mouse Model. Processes 2020;8(1):102.   DOI
14 Zappala CJ, Latsi PI, Nicholson AG, Colby TV, Cramer D, Renzoni EA, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. European Respiratory Journal 2010;35(4):830-6.   DOI
15 Oda K, Ishimoto H, Yatera K, Naito K, Ogoshi T, Yamasaki K, et al. High-resolution CT scoring system-based grading scale predicts the clinical outcomes in patients with idiopathic pulmonary fibrosis. Respiratory research 2014;15(1):1-9.
16 Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. American journal of respiratory and critical care medicine 2000;161(4):1172-8.   DOI
17 張介賓, 景岳全書. 서울: 한미의학; 2006.
18 Rosas IO, Dellaripa PF, Lederer DJ, Khanna D, Young LR, Martinez FJ. Interstitial lung disease: NHLBI workshop on the primary prevention of chronic lung diseases. Annals of the American Thoracic Society 2014;11(Supplement 3):S169-S77.   DOI
19 Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. The Lancet 2017;389(10082):1941-52.   DOI
20 Baek HJ, Bhang YH, Kim JH, Kim SJ, Kim KI, Lee BJ, et al. A Retrospective Study of Chronic Pulmonary Disease Patients Treated with Chungsangboha-tang : IgE, eosinophil, PFT. J Int Korean Med 2016;37(3):484-94.
21 Collard HR. King Jr TE, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. American journal of respiratory and critical care medicine 2003; 168(5):538-42.   DOI
22 Network IPFCR. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. New England Journal of Medicine 2012;366(21):1968-77.   DOI